SIDE: Self-supervised Intermediate Domain Exploration for Source-free Domain Adaptation

Domain adaptation aims to alleviate the domain shift when transferring the knowledge learned from the source domain to the target domain. Due to privacy issues, source-free domain adaptation (SFDA), where source data is unavailable during adaptation, has recently become very demanding yet challenging. Existing SFDA methods focus on either self-supervised learning of target samples or reconstruction of virtual source data. The former overlooks the transferable knowledge in the source model, whilst the latter introduces even more uncertainty. To address the above issues, this paper proposes self-supervised intermediate domain exploration (SIDE) that effectively bridges the domain gap with an intermediate domain, where samples are cyclically filtered out in a self-supervised fashion. First, we propose cycle intermediate domain filtering (CIDF) to cyclically select intermediate samples with similar distributions over source and target domains. Second, with the aid of those intermediate samples, an inter-domain gap transition (IDGT) module is developed to mitigate possible distribution mismatches between the source and target data. Finally, we introduce cross-view consistency learning (CVCL) to maintain the intrinsic class discriminability whilst adapting the model to the target domain. Extensive experiments on three popular benchmarks, i.e. Office-31, Office-Home and VisDA-C, show that our proposed SIDE achieves competitive performance against state-of-the-art methods.Comment: code at https://github.com/se111/SID

Neural Conversation Generation with Auxiliary Emotional Supervised Models

An important aspect of developing dialogue agents involves endowing a conversation system with emotion perception and interaction. Most existing emotion dialogue models lack the adaptability and extensibility of different scenes because of their limitation to require a specified emotion category or their reliance on a fixed emotional dictionary. To overcome these limitations, we propose a neural conversation generation with auxiliary emotional supervised model (nCG-ESM) comprising a sequence-to-sequence (Seq2Seq) generation model and an emotional classifier used as an auxiliary model. The emotional classifier was trained to predict the emotion distributions of the dialogues, which were then used as emotion supervised signals to guide the generation model to generate diverse emotional responses. The proposed nCG-ESM is flexible enough to generate responses with emotional diversity, including specified or unspecified emotions, which can be adapted and extended to different scenarios. We conducted extensive experiments on the popular dataset of Weibo post--response pairs. Experimental results showed that the proposed model was capable of producing more diverse, appropriate, and emotionally rich responses, yielding substantial gains in diversity scores and human evaluations.Peer reviewe

Risk of hepatitis B virus reactivation and its effect on survival in advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy and lenvatinib plus programmed death receptor-1 inhibitors

BackgroundHepatitis B virus (HBV) reactivation is a common complication in hepatocellular carcinoma (HCC) patients treated with chemotherapy or immunotherapy. This study aimed to evaluate the risk of HBV reactivation and its effect on survival in HCC patients treated with HAIC and lenvatinib plus PD1s.MethodsWe retrospectively collected the data of 213 HBV-related HCC patients who underwent HAIC and lenvatinib plus PD1s treatment between June 2019 to June 2022 at Sun Yat-sen University, China. The primary outcome was the risk of HBV reactivation. The secondary outcomes were overall survival (OS), progression−free survival (PFS), and treatment−related adverse events.ResultsSixteen patients (7.5%) occurred HBV reactivation in our study. The incidence of HBV reactivation was 5% in patients with antiviral prophylaxis and 21.9% in patients without antiviral prophylaxis, respectively. The logistic regression model indicated that for HBV reactivation, lack of antiviral prophylaxis (P=0.003) and tumor diameter (P=0.036) were independent risk factors. The OS and PFS were significantly shorter in the HBV reactivation group than the non-reactivation group (P=0.0023 and P=0.00073, respectively). The number of AEs was more in HBV reactivation group than the non-reactivation group, especially hepatic AEs.ConclusionHBV reactivation may occur in HCC patients treated with HAIC and lenvatinib plus PD1s. Patients with HBV reactivation had shorter survival time compared with non-reactivation. Therefore, HBV-related HCC patients should undergo antiviral therapy and HBV-DNA monitoring before and during the combination treatment

A β-glucosidase hyper-production Trichoderma reesei mutant reveals a potential role of cel3D in cellulase production

Abstract Background The conversion of cellulose by cellulase to fermentable sugars for biomass-based products such as cellulosic biofuels, biobased fine chemicals and medicines is an environment-friendly and sustainable process, making wastes profitable and bringing economic benefits. Trichoderma reesei is the well-known major workhorse for cellulase production in industry, but the low β-glucosidase activity in T. reesei cellulase leads to inefficiency in biomass degradation and limits its industrial application. Thus, there are ongoing interests in research to develop methods to overcome this insufficiency. Moreover, although β-glucosidases have been demonstrated to influence cellulase production and participate in the regulation of cellulase production, the underlying mechanism remains unclear. Results The T. reesei recombinant strain TRB1 was constructed from T. reesei RUT-C30 by the T-DNA-based mutagenesis. Compared to RUT-C30, TRB1 displays a significant enhancement of extracellular β-glucosidase (BGL1) activity with 17-fold increase, a moderate increase of both the endoglucanase (EG) activity and the exoglucanase (CBH) activity, a minor improvement of the total filter paper activity, and a faster cellulase induction. This superiority of TRB1 over RUT-C30 is independent on carbon sources and improves the saccharification ability of TRB1 cellulase on pretreated corn stover. Furthermore, TRB1 shows better resistance to carbon catabolite repression than RUT-C30. Secretome characterization of TRB1 shows that the amount of CBH, EG and BGL in the supernatant of T. reesei TRB1 was indeed increased along with the enhanced activities of these three enzymes. Surprisingly, qRT-PCR and gene cloning showed that in TRB1 β-glucosidase cel3D was mutated through the random insertion by AMT and was not expressed. Conclusions The T. reesei recombinant strain TRB1 constructed in this study is more desirable for industrial application than the parental strain RUT-C30, showing extracellular β-glucosidase hyper production, high cellulase production within a shorter time and a better resistance to carbon catabolite repression. Disruption of β-glucosidase cel3D in TRB1 was identified, which might contribute to the superiority of TRB1 over RUT-C30 and might play a role in the cellulase production. These results laid a foundation for future investigations to further improve cellulase enzymatic efficiency and reduce cost for T. reesei cellulase production.http://deepblue.lib.umich.edu/bitstream/2027.42/134636/1/12934_2016_Article_550.pd

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

Background/purpose: The prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is generally poor and hepatectomy is optional for these patients. This study aims to explore the survival benefits of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) for resectable HCC with PVTT.Methods: This retrospective study included 120 resectable HCC patients with PVTT who underwent hepatectomy, from January 2017 to January 2021 at Sun Yat-sen University Cancer Center. Of these patients, the overall survival (OS) and recurrence-free survival (RFS) of 55 patients who received hepatectomy alone (Surgery group) and 65 patients who received neoadjuvant HAIC followed by hepatectomy (HAIC-Surgery group) were compared. Logistic regression analysis was conducted to develop a model predicting the response to neoadjuvant HAIC.Results: The OS rates for the HAIC-Surgery group at 1, 3, and 5 years were 94.9%, 78%, and 66.4%, respectively, compared with 84.6%, 47.6%, and 37.2% in the Surgery group (p < 0.001). The RFS rates were 88.7%, 56.2%, and 38.6% versus 84.9%, 38.3%, and 22.6% (p = 0.002). The subgroup analysis revealed that the survival benefit of neoadjuvant HAIC was limited to patients who responded to it. The logistic model, consisting of AFP and CRP, that predicted the response to neoadjuvant HAIC performed well, with an area under the ROC curve (AUC) of 0.756.Conclusion: Neoadjuvant HAIC followed by hepatectomy is associated with a longer survival outcome than hepatectomy alone for HCC patients with PVTT and the survival benefit is limited to patients who respond to neoadjuvant FOLFOX-HAIC

CW dual-frequency MOPA laser with frequency separation of 45 GHz

A CW dual-frequency master oscillator power amplifier (MOPA) laser system with dozens of gigahertz (GHz) frequency separation is presented. The MOPA system consists of a monolithic microchip seed laser and a double-end pumped traveling wave power amplifier. The short length of seed laser cavity guarantees the seed signal with a large frequency separation (above 53 GHz) but low output power (below 247.8 mW). By adding a long and low-doped active medium laser amplifier stage, a significant increase in laser power and an improvement in beam quality are obtained. After fine temperature tuning of seed laser cavity for spectra matching , a 2.40 W dual-frequency laser signal with 45 GHz frequency separation is achieved

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma

Background: Systemic chemotherapy (SC) remains the only first-line treatment for unresectable intrahepatic cholangiocarcinoma (iCCA). Hepatic arterial infusion chemotherapy (HAIC) has been recently proven to be effective in managing hepatocellular carcinoma (HCC). Hence, our study aims to investigate the safety and efficacy of HAIC in treating unresectable iCCA patients.Methods: We reviewed 146 patients with unresectable iCCA who had received HAIC or SC between March 2016 and March 2022 in a retrospective manner. Outcomes of patients and safety were compared between the HAIC and SC groups.Results: There were 75 and 71 patients in the HAIC and SC groups, respectively. The median OS in the HAIC and SC groups was 18.0 and 17.8 months (p = 0.84), respectively. The median PFS in the HAIC and SC groups was 10.8 and 11.4 months (p = 0.59), respectively. However, the HAIC group had significantly longer intrahepatic progression-free survival (IPFS) than the SC group (p = 0.035). The median IPFS in the HAIC and SC groups was 13.7 and 11.4 months, respectively. According to the OS (p = 0.047) and PFS (p = 0.009), single-tumor patients in the HAIC group appeared to benefit more. In addition, the overall incidence of adverse events (AEs) was lower in the HAIC group than that in the SC group.Conclusion: Our study revealed that HAIC was a safe and effective therapeutic regimen for unresectable iCCA with better intrahepatic tumor control when compared to SC. Meanwhile, patients with single tumor were more likely to benefit from HAIC than SC